These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

331 related items for PubMed ID: 21254949

  • 1. Ivabradine: recent and potential applications in clinical practice.
    Riccioni G.
    Expert Opin Pharmacother; 2011 Feb; 12(3):443-50. PubMed ID: 21254949
    [Abstract] [Full Text] [Related]

  • 2. Ivabradine: beyond heart rate control.
    Riccioni G, Vitulano N, D'Orazio N.
    Adv Ther; 2009 Jan; 26(1):12-24. PubMed ID: 19165437
    [Abstract] [Full Text] [Related]

  • 3. Rationale and design of a randomized, double-blind, placebo-controlled trial of ivabradine in patients with stable coronary artery disease and left ventricular systolic dysfunction: the morBidity-mortality EvAlUaTion of the I(f) inhibitor ivabradine in patients with coronary disease and left ventricULar dysfunction (BEAUTIFUL) study.
    Fox K, Ferrari R, Tendera M, Steg PG, Ford I, BEAUTIFUL Steering Committee.
    Am Heart J; 2006 Nov; 152(5):860-6. PubMed ID: 17070146
    [Abstract] [Full Text] [Related]

  • 4. Innovation in coronary artery disease and heart failure: clinical benefits of pure heart rate reduction with ivabradine.
    Canet E, Lerebours G, Vilaine JP.
    Ann N Y Acad Sci; 2011 Mar; 1222():90-9. PubMed ID: 21434947
    [Abstract] [Full Text] [Related]

  • 5. Role of heart rate in cardiovascular diseases: how the results of the BEAUTIFUL study change clinical practice.
    Bruguera Cortada J, Varela A.
    Am J Cardiovasc Drugs; 2009 Mar; 9 Suppl 1():9-12. PubMed ID: 20000882
    [Abstract] [Full Text] [Related]

  • 6. Heart rate in ischemic heart disease. The innovation of ivabradine: more than pure heart rate reduction.
    Rosano GM, Vitale C, Volterrani M.
    Adv Ther; 2010 Apr; 27(4):202-10. PubMed ID: 20495895
    [Abstract] [Full Text] [Related]

  • 7. Impact of a pure reduction in heart rate for the treatment of left ventricular dysfunction: clinical benefits of ivabradine in the BEAUTIFUL trial.
    Danchin N.
    Therapie; 2009 Apr; 64(2):111-4. PubMed ID: 19664404
    [Abstract] [Full Text] [Related]

  • 8. Rate control with ivabradine: angina pectoris and beyond.
    Parakh N, Bhargava B.
    Am J Cardiovasc Drugs; 2011 Apr; 11(1):1-12. PubMed ID: 21090826
    [Abstract] [Full Text] [Related]

  • 9. The importance of reducing heart rate in cardiovascular diseases: effects of Ivabradine.
    Vizzardi E, Bonadei I, D'Aloia A, Del Magro F, Piovanelli B, Bontempi L, Curnis A, Dei Cas L.
    Minerva Med; 2011 Oct; 102(5):373-9. PubMed ID: 22193347
    [Abstract] [Full Text] [Related]

  • 10. Resting heart rate in cardiovascular disease.
    Fox K, Borer JS, Camm AJ, Danchin N, Ferrari R, Lopez Sendon JL, Steg PG, Tardif JC, Tavazzi L, Tendera M, Heart Rate Working Group.
    J Am Coll Cardiol; 2007 Aug 28; 50(9):823-30. PubMed ID: 17719466
    [Abstract] [Full Text] [Related]

  • 11. Characterization of the heart rate-lowering action of ivabradine, a selective I(f) current inhibitor.
    Borer JS, Le Heuzey JY.
    Am J Ther; 2008 Aug 28; 15(5):461-73. PubMed ID: 18806523
    [Abstract] [Full Text] [Related]

  • 12. Ivabradine: I(f) inhibition in the management of stable angina pectoris and other cardiovascular diseases.
    Tardif JC.
    Drugs Today (Barc); 2008 Mar 28; 44(3):171-81. PubMed ID: 18536779
    [Abstract] [Full Text] [Related]

  • 13. Relationship between ivabradine treatment and cardiovascular outcomes in patients with stable coronary artery disease and left ventricular systolic dysfunction with limiting angina: a subgroup analysis of the randomized, controlled BEAUTIFUL trial.
    Fox K, Ford I, Steg PG, Tendera M, Robertson M, Ferrari R, BEAUTIFUL Investigators.
    Eur Heart J; 2009 Oct 28; 30(19):2337-45. PubMed ID: 19720635
    [Abstract] [Full Text] [Related]

  • 14. Beneficial effect of ivabradine against cardiovascular diseases.
    Gammone MA, Riccioni G, Massari F, D'Orazio N.
    Front Biosci (Schol Ed); 2020 Mar 01; 12(1):161-172. PubMed ID: 32114453
    [Abstract] [Full Text] [Related]

  • 15. Safety of ivabradine in patients with coronary artery disease and left ventricular systolic dysfunction (from the BEAUTIFUL Holter Substudy).
    Tendera M, Talajic M, Robertson M, Tardif JC, Ferrari R, Ford I, Steg PG, Fox K, BEAUTIFUL Investigators.
    Am J Cardiol; 2011 Mar 15; 107(6):805-11. PubMed ID: 21247517
    [Abstract] [Full Text] [Related]

  • 16. Ivabradine for patients with stable coronary artery disease and left-ventricular systolic dysfunction (BEAUTIFUL): a randomised, double-blind, placebo-controlled trial.
    Fox K, Ford I, Steg PG, Tendera M, Ferrari R, BEAUTIFUL Investigators.
    Lancet; 2008 Sep 06; 372(9641):807-16. PubMed ID: 18757088
    [Abstract] [Full Text] [Related]

  • 17. Ivabradine -- the first selective sinus node I(f) channel inhibitor in the treatment of stable angina.
    Sulfi S, Timmis AD.
    Int J Clin Pract; 2006 Feb 06; 60(2):222-8. PubMed ID: 16451297
    [Abstract] [Full Text] [Related]

  • 18. Heart rate as a treatable cardiovascular risk factor.
    Tardif JC.
    Br Med Bull; 2009 Feb 06; 90():71-84. PubMed ID: 19474056
    [Abstract] [Full Text] [Related]

  • 19. Ivabradine: pharmacodynamic aspects of its clinical use.
    Stieber J.
    Methods Find Exp Clin Pharmacol; 2008 Oct 06; 30(8):633-41. PubMed ID: 19088948
    [Abstract] [Full Text] [Related]

  • 20. Heart rate in coronary syndromes and heart failure.
    Orso F, Baldasseroni S, Maggioni AP.
    Prog Cardiovasc Dis; 2009 Oct 06; 52(1):38-45. PubMed ID: 19615492
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 17.